Tirzepatide vs every other GLP-1 drug, ranked.
Tirzepatide is the most-effective GLP-1 / GIP dual agonist on the market in 2026, but it's not the only weight-loss or diabetes peptide drug. Mazdutide, Orforglipron, Tesofensine, Liraglutide, and Semaglutide all compete or complement, and Tirzepatide itself goes by three brand names (Mounjaro, Zepbound, and compounded versions) that confuse people daily. Below is the complete comparison: how Tirzepatide stacks up against every major rival, what's the same and what's different between Mounjaro and Zepbound, and which of the upcoming pipeline drugs are about to challenge it.
🔑 Key Takeaways
- Tirzepatide currently wins. Best head-to-head data vs Semaglutide, Liraglutide, and the older GLP-1 monoagonists. Retatrutide (a triple agonist) is the main rival in late-stage trials.
- Mounjaro = Zepbound = compounded tirzepatide. Same molecule, different brand for different FDA indications. Mounjaro for diabetes, Zepbound for obesity and sleep apnea, compounded versions for shortage-era access.
- Mazdutide is the closest pipeline rival. Dual GLP-1 / glucagon agonist out of China, late-stage trial data shows comparable weight loss with potentially better metabolic profile.
- Orforglipron is the first oral GLP-1 pill that actually works. Lilly's once-daily tablet, no injection required, but weight loss is slightly behind tirzepatide.
- Tesofensine is the wildcard. Not a GLP-1, works through monoamine reuptake inhibition. Strong weight loss data but neurological side effect concerns.
Tirzepatide vs Semaglutide
The original GLP-1 vs dual agonist matchup. In the head-to-head SURPASS-2 trial, tirzepatide outperformed semaglutide on weight loss, A1C reduction, and cardiovascular markers.
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 monoagonist |
| Brand names | Mounjaro, Zepbound | Ozempic, Wegovy, Rybelsus (oral) |
| Average weight loss (72 weeks, max dose) | ~22.5% | ~15% |
| A1C reduction (T2D) | ~2.4 percentage points | ~1.9 percentage points |
| Triglyceride drop | 15-25% | 10-20% |
| GI side effect rate | Comparable; slightly more at 15mg dose | Slightly less at equivalent dose milestones |
| Cost (cash, US) | $1,000-1,300/month brand | $900-1,300/month brand |
| Best for | Faster, larger weight loss; better A1C control | Established cardiovascular outcomes data; oral option available |
For most users prioritizing weight loss magnitude, tirzepatide wins. For users prioritizing established cardiovascular outcomes data (SELECT trial), semaglutide has more longitudinal evidence. Switching from one to the other is increasingly common; see our switching guide. Full breakdown at tirzepatide vs semaglutide.
Tirzepatide vs Mazdutide
Mazdutide is the closest active pipeline rival, a dual GLP-1 / glucagon receptor agonist developed by Innovent Biologics in China. Approved in China in 2025; not yet FDA-approved in the US as of 2026.
| Factor | Tirzepatide | Mazdutide |
|---|---|---|
| Receptor target | GLP-1 + GIP | GLP-1 + Glucagon |
| Average weight loss (48 weeks, max dose) | ~22.5% | ~17-19% (GLORY-1 trial) |
| Energy expenditure effect | Modest improvement | Stronger thermogenic effect via glucagon |
| Liver fat reduction | Strong | Strongest of any GLP-1 class drug to date |
| FDA status (US, 2026) | Approved (Mounjaro, Zepbound) | Not approved; trial-stage |
| Best for | Maximum weight loss + diabetes control | NAFLD / metabolic-dysfunction-associated fatty liver, future option for fatty liver-dominant phenotypes |
Is mazdutide better than tirzepatide? Not for weight loss, tirzepatide still produces larger reductions at currently studied doses. For fatty liver and metabolic dysfunction phenotypes, mazdutide may eventually win because of its dual GLP-1 / glucagon mechanism. Final verdict depends on US FDA approval timeline.
Tirzepatide vs Orforglipron
Orforglipron is Eli Lilly's oral, non-peptide small-molecule GLP-1 agonist, the first orally bioavailable GLP-1 that produces injectable-level weight loss. FDA-approved as Foundayo in 2026 with no food restriction.
| Factor | Tirzepatide | Orforglipron (Foundayo) |
|---|---|---|
| Format | Subcutaneous injection, weekly | Oral tablet, daily |
| Mechanism | GLP-1 + GIP dual agonist (peptide) | GLP-1 monoagonist (small molecule) |
| Average weight loss (72 weeks, max dose) | ~22.5% | ~14-15% (ACHIEVE / ATTAIN trials) |
| Food restrictions | None | None (unlike Rybelsus) |
| Injection burden | Weekly self-injection | Daily pill, no injection |
| Cost (US, 2026) | $1,000-1,300/month brand; $200-400 compounded | ~$800-1,000/month brand |
| Best for | Maximum weight loss; established efficacy | Needle-averse users; daily routine fits better than weekly injection |
For people who don't want needles, orforglipron is the breakthrough. For maximum weight loss, tirzepatide still leads, though Lilly's pipeline includes oral tirzepatide-equivalent dual agonists that may close the gap in 2027-2028.
Tirzepatide vs Tesofensine
Tesofensine is the outlier in this comparison. It's not a GLP-1 or GIP drug at all, it's a triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) originally developed for Parkinson's that turned out to be a strong appetite suppressant.
| Factor | Tirzepatide | Tesofensine |
|---|---|---|
| Mechanism | GLP-1 + GIP receptor agonist | Triple monoamine reuptake inhibitor (dopamine, NE, serotonin) |
| Format | Weekly subcutaneous injection | Daily oral tablet |
| Average weight loss (24-48 weeks) | ~22.5% | ~10-12% |
| Side effect profile | GI dominant (nausea, vomiting) | CNS dominant (dry mouth, insomnia, blood pressure increase, mood effects) |
| FDA status | Approved | Not FDA-approved in US; approved in Mexico, EU access via specialty pharmacies |
| Best for | Standard weight loss; metabolic improvement | Users who don't respond to GLP-1 drugs or want a different mechanism |
Tirzepatide has stronger published evidence, better safety profile, and stronger weight loss. Tesofensine is a niche option for non-GLP-1-responders. Stacking the two has been explored experimentally but isn't standard.
Tirzepatide vs Liraglutide
Liraglutide (Saxenda for obesity, Victoza for diabetes) was the first widely-used GLP-1 monoagonist. It requires daily injection instead of weekly, and weight loss is substantially smaller.
| Factor | Tirzepatide | Liraglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP | GLP-1 monoagonist |
| Injection frequency | Once weekly | Daily |
| Average weight loss (52 weeks) | ~22.5% | ~6-8% |
| A1C reduction | ~2.4 points | ~1.2 points |
| Cost | $1,000-1,300/month brand | $700-1,400/month brand |
| Best for | Maximum effect, less injection burden | Largely outdated; replaced by semaglutide and tirzepatide for most use cases |
Liraglutide is essentially obsolete for new patients now that semaglutide and tirzepatide exist. The only remaining use cases are: patients already stable on liraglutide who tolerate it well, or insurance coverage that favors it over newer drugs.
Is Tirzepatide the Same as Mounjaro, Zepbound, or Compounded Versions?
Yes, all three deliver the same active molecule: tirzepatide. The differences are in branding, FDA indication, formulation, and price.
| Product | FDA indication | Format | Typical cash cost |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | Pre-filled pen (KwikPen) | $1,000-1,300/month |
| Zepbound | Obesity / weight management; obstructive sleep apnea in obesity | Pre-filled pen, single-dose vials (2024 launch) | $1,000-1,300/month; vials $349-549/month direct from Lilly |
| Compounded tirzepatide | None (not FDA-approved as a compound) | Multi-dose vial, reconstituted with bacteriostatic water | $150-400/month via telehealth or compounding pharmacy |
Is compounded tirzepatide the same as Zepbound? Pharmacologically yes, the molecule is identical. Practically, compounded versions are made by 503A/503B compounding pharmacies (not Lilly), so the manufacturing controls, sterility testing, and dose accuracy vary by pharmacy. Reputable compounders are essentially equivalent; unverified vendors are not. See our compounded tirzepatide guide for sourcing.
Is Tirzepatide the Same as Ozempic?
No. Ozempic is the brand name for semaglutide (a different molecule). Tirzepatide is sold as Mounjaro and Zepbound. Both are GLP-1-class weight loss / diabetes drugs, but tirzepatide adds GIP receptor activity that semaglutide doesn't have, which is why tirzepatide produces larger weight loss in head-to-head trials.
What Does Tirzepatide Do That Semaglutide Does Not?
Three meaningful differences:
- GIP receptor activation. Tirzepatide activates the GIP (glucose-dependent insulinotropic polypeptide) receptor in addition to GLP-1. GIP improves insulin secretion in response to nutrients and may contribute to better satiety and metabolic flexibility.
- Larger weight loss at equivalent dose escalation. SURPASS-2 head-to-head showed tirzepatide ~22.5% vs semaglutide ~15% at max doses over 72 weeks.
- Stronger A1C reduction in diabetics. ~2.4 percentage points vs semaglutide's ~1.9 in T2D patients.
What semaglutide does that tirzepatide doesn't (yet): established cardiovascular outcomes data from the SELECT trial (semaglutide reduced major adverse cardiovascular events by 20% in non-diabetic obese patients with prior CV disease). Tirzepatide's CV outcomes trial (SURPASS-CVOT) is ongoing.
Frequently Asked Questions
Medical disclaimer: This article is for educational and informational purposes only and is not medical advice. All weight-loss and diabetes drugs require a prescription and medical supervision. The comparisons in this article are based on published clinical trial data and US regulatory status as of May 2026; trial results and approval timelines change. Talk to your prescriber about which option fits your specific medical history, comorbidities, and goals.